We describe the landscape of genomic alterations in cutaneous melanomas through DNA, RNA, and protein-based analysis of 333 primary and/or metastatic melanomas from 331 patients. We establish a framework for genomic classification into one of four subtypes based on the pattern of the most prevalent significantly mutated genes: mutant BRAF, mutant RAS, mutant NF1, and Triple-WT (wild-type). Integrative analysis reveals enrichment of KIT mutations and focal amplifications and complex structural rearrangements as a feature of the Triple-WT subtype. We found no significant outcome correlation with genomic classification, but samples assigned a transcriptomic subclass enriched for immune gene expression associated with lymphocyte infiltrate on pathology review and high LCK protein expression, a T cell marker, were associated with improved patient survival. This clinicopathological and multi-dimensional analysis suggests that the prognosis of melanoma patients with regional metastases is influenced by tumor stroma immunobiology, offering insights to further personalize therapeutic decision-making.
Copyright © 2015 Elsevier Inc. All rights reserved.
GAB2 amplifications refine molecular classification of melanoma.Clin Cancer Res. 2009 Jul 1;15(13):4288-91. doi: 10.1158/1078-0432.CCR-09-0280. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509136 Free PMC article.
Improving melanoma classification by integrating genetic and morphologic features.Version 2. PLoS Med. 2008 Jun 3;5(6):e120. doi: 10.1371/journal.pmed.0050120. PLoS Med. 2008. PMID: 18532874 Free PMC article.
Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.Clin Cancer Res. 2006 Aug 1;12(15):4499-505. doi: 10.1158/1078-0432.CCR-05-2447. Clin Cancer Res. 2006. PMID: 16899595
Toward a molecular classification of melanoma.J Clin Oncol. 2007 Apr 20;25(12):1606-20. doi: 10.1200/JCO.2006.06.0442. J Clin Oncol. 2007. PMID: 17443002 Review.
Developments in targeted therapy in melanoma.Eur J Surg Oncol. 2017 Mar;43(3):581-593. doi: 10.1016/j.ejso.2016.10.014. Epub 2016 Nov 5. Eur J Surg Oncol. 2017. PMID: 27923592 Review.
Cited by 640 articles
Predictive Gene Signature for Pyrazolopyrimidine Derivative c-Src Inhibitor 10a Sensitivity in Melanoma Cells.ACS Med Chem Lett. 2020 Feb 18;11(5):928-932. doi: 10.1021/acsmedchemlett.9b00679. eCollection 2020 May 14. ACS Med Chem Lett. 2020. PMID: 32435407
The landscape of chromothripsis across adult cancer types.Nat Commun. 2020 May 8;11(1):2320. doi: 10.1038/s41467-020-16134-7. Nat Commun. 2020. PMID: 32385320 Free PMC article.
Mutational signatures are jointly shaped by DNA damage and repair.Nat Commun. 2020 May 1;11(1):2169. doi: 10.1038/s41467-020-15912-7. Nat Commun. 2020. PMID: 32358516 Free PMC article.
PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.Nat Commun. 2020 May 1;11(1):2135. doi: 10.1038/s41467-020-15959-6. Nat Commun. 2020. PMID: 32358509 Free PMC article.
A twelve-gene signature for survival prediction in malignant melanoma patients.Ann Transl Med. 2020 Mar;8(6):312. doi: 10.21037/atm.2020.02.132. Ann Transl Med. 2020. PMID: 32355756 Free PMC article.
- UL1 TR000005/TR/NCATS NIH HHS/United States
- P30 CA016672/CA/NCI NIH HHS/United States
- U24 CA143882/CA/NCI NIH HHS/United States
- U54 HG003067/HG/NHGRI NIH HHS/United States
- U24 CA143835/CA/NCI NIH HHS/United States
- U24 CA143866/CA/NCI NIH HHS/United States
- U24 CA143845/CA/NCI NIH HHS/United States
- U24 CA143799/CA/NCI NIH HHS/United States
- T32 GM007753/GM/NIGMS NIH HHS/United States
- U54 HG003273/HG/NHGRI NIH HHS/United States
- P30 CA008748/CA/NCI NIH HHS/United States
- U24 CA144025/CA/NCI NIH HHS/United States
- R01 CA163896/CA/NCI NIH HHS/United States
- U24 CA180951/CA/NCI NIH HHS/United States
- U24 CA143840/CA/NCI NIH HHS/United States
- U24 CA143843/CA/NCI NIH HHS/United States
- U24 CA143858/CA/NCI NIH HHS/United States
- U24 CA143848/CA/NCI NIH HHS/United States
- P50 CA121974/CA/NCI NIH HHS/United States
- U54 HG003079/HG/NHGRI NIH HHS/United States
- U24 CA143883/CA/NCI NIH HHS/United States
- U24 CA143867/CA/NCI NIH HHS/United States